Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Implant or insert
Reexamination Certificate
2005-05-31
2005-05-31
Azpuru, Carlos A. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Implant or insert
C424S427000, C424S430000, C424S433000, C424S434000, C424S436000, C424S451000, C424S464000
Reexamination Certificate
active
06899888
ABSTRACT:
This invention provides: 1) a method of treating androgen-deprivation induced osteoporosis and/or bone fractures and/or loss of Bone Mineral Density (BMD) in a male subject suffering from prostate cancer; 2) a method of preventing androgen-deprivation induced osteoporosis and/or bone fractures and/or loss of Bone Mineral Density (BMD) in a male subject suffering from prostate cancer; 3) a method of suppressing or inhibiting androgen-deprivation induced osteoporosis and/or bone fractures and/or loss of BMD in a male subject suffering from prostate cancer; and 4) a method of reducing the risk of developing androgen-deprivation induced osteoporosis and/or bone fractures and/or loss of BMD in a male subject suffering from prostate cancer, by administering to the subject a pharmaceutical composition comprising an anti-estrogen agent and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof as described herein.
REFERENCES:
patent: 5468488 (1995-11-01), Wahi
patent: 6262098 (2001-07-01), Huebner et al.
patent: 6265448 (2001-07-01), Steiner et al.
patent: 6410043 (2002-06-01), Steiner et al.
patent: 6413533 (2002-07-01), Steiner et al.
patent: 6413534 (2002-07-01), Steiner et al.
patent: 6413535 (2002-07-01), Steiner et al.
patent: 6632447 (2003-10-01), Steiner et al.
Smith, M.R., slide presntation at the 4thInternational Prosate Cancer Congress, Grand Bahama Island, Jul. 15-18, 2004.*
Mittan, D. et al, The Journal of Clinical Endocrinology & Metabolism (2002) vol. 87, No. 8 3656-3661.*
Berrutti A. et al, Drugs Aging (2002) vol. 19, No. 12, 899-910.*
Smith M.R., cancer Reviews (2002) vol. 21, 159-166.*
O'Brien Frank M. et al “Insulin-like Growth Fact I and Prostate Cancer”, 2001 Elsevier Science Inc, Urology 58;1-7, 2001.
Horwitz Eric M. et al “Subset Analysis of RTOG 85031 and 86-10 Indicates An Advantage For Long-Term vs. Short-Terms Adjuvant Hormones For Patients With Locally Advanced Nonmetastatic Prostate Cancer Treated with Radiation Therapy”, Int. J. Radiation Oncology Biol. Phys. vol. 49, No. 4 pp. 947-956, 2001, Elsevier Science Inc.
Messing Edward M. et al “Immediate Hormonal Therapy Compared With Observation After Radical Prostatectomy and Pelvic Lymphadenectomy in Men With Node-Positive Prostate Cancer” The New England Journal of Medicine, 1999 vol. 341, No. 24.
Newling Don W.W. “Early Versus Late Androgen Deprivation Therapy in Metastalic Disease”, Elsevier Science Inc, Urology 58 (supplement 2A), Aug. 2001.
Stege Reinhard et al. “Potential Side-Effects of Endocrine Treatment of Long Duration in Prostate Cancer” The Prostate Supplement 10:38-42, 2000.
Goodson Max J. “Dental Applications” vol. II, Chapter 6.
Steiner Mitchell S.
Veverka Karen A.
Azpuru Carlos A.
Cohen Mark S.
Eitan, Pearl, Latzer & Cohen Zedek LLP
Otx, Inc.
LandOfFree
Prevention and treatment of androgen-deprivation induced... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Prevention and treatment of androgen-deprivation induced..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prevention and treatment of androgen-deprivation induced... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3380278